Polymer nanoparticulate drug delivery and combination cancer therapy

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin.62(1),10–29 (2012).
  MedlineGoogle Scholar
• 2  Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol.17(6),1794–1801 (1999).
  Medline CASGoogle Scholar
• 3  Gardner GJ, Jewell EL. Current and future directions of clinical trials for ovarian cancer. Cancer Control18(1),44–51 (2011).
  MedlineGoogle Scholar
• 4  Graham JS, Cassidy J. Adjuvant therapy in colon cancer. Expert Rev. Anticancer Ther.12(1),99–109 (2012).
  Medline CASGoogle Scholar
• 5  van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet378(9804),1741–1755 (2011).
  MedlineGoogle Scholar
• 6  Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J. Drug Deliv. doi:10.1155/2012/915375 (2012) (Epub ahead of print).
  Google Scholar
• 7  Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, Phase 3 trial. Lancet379(9816),633–640 (2012).
  Medline CASGoogle Scholar
• 8  Bliesath J, Huser N, Omori M et al. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett.322(1),113–118 (2012).
  Medline CASGoogle Scholar
• 9  Holt SV, Logie A, Odedra R et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br. J. Cancer106(5),858–866 (2012).
  Medline CASGoogle Scholar
• 10  Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev. Anticancer Ther.11(9),1379–1390 (2011).
  MedlineGoogle Scholar
• 11  Kinsella P, Clynes M, Amberger-Murphy V. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. J. Neurooncol.101(2),189–198 (2011).
  Medline CASGoogle Scholar
• 12  Larbouret C, Gaborit N, Chardes T et al. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors’ down-regulation and dimers’ disruption. Neoplasia14(2),121–130 (2012).
  Medline CASGoogle Scholar
• 13  Pichot CS, Hartig SM, Xia L et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br. J. Cancer101(1),38–47 (2009).
  Medline CASGoogle Scholar
• 14  Von Minckwitz G, Loibl S, Untch M. What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Oncology26(1),20–26 (2012).
  MedlineGoogle Scholar
• 15  Wu CL, Ping SY, Yu CP, Yu DS. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J. Med. Sci.28(4),194–203 (2012).
  Medline CASGoogle Scholar
• 16  Duncan R. Polymer conjugates for drug targeting. From inspired to inspiration! J. Drug Target14(6),333–335 (2006).▪ Provides a better understanding of current drug delivery approaches.
  Medline CASGoogle Scholar
• 17  Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol.26(1),57–64 (2008).
  Medline CASGoogle Scholar
• 18  Malam Y, Lim EJ, Seifalian AM. Current trends in the application of nanoparticles in drug delivery. Curr. Med. Chem.18(7),1067–1078 (2011).
  Medline CASGoogle Scholar
• 19  McNeil SE. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol. Biol.697,3–8 (2011).
  Medline CASGoogle Scholar
• 20  Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med.63,185–198 (2012).
  Medline CASGoogle Scholar
• 21  Yang H, Liu C, Yang DF, Zhang HS, Xi ZG. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J. Appl. Toxicol.29(1),69–78 (2009).
  MedlineGoogle Scholar
• 22  Jin H, Heller DA, Sharma R, Strano MS. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano3(1),149–158 (2009).
  Medline CASGoogle Scholar
• 23  He CB, Hu YP, Yin LC, Tang C, Yin CH. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials31(13),3657–3666 (2010).
  Medline CASGoogle Scholar
• 24  Cho EC, Au L, Zhang Q, Xia YN. The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells. Small6(4),517–522 (2010).
  Medline CASGoogle Scholar
• 25  Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev.63(3),131–135 (2011).▪▪ Informative review explaining tumor-preferential drug delivery approaches.
  Medline CASGoogle Scholar
• 26  Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther.83(5),761–769 (2008).
  Medline CASGoogle Scholar
• 27  Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. (197),3–53 (2010).
  MedlineGoogle Scholar
• 28  Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst.1(3),242–250 (2005).
  Medline CASGoogle Scholar
• 29  West KR, Otto S. Reversible covalent chemistry in drug delivery. Curr. Drug Discov. Technol.2(3),123–160 (2005).▪▪ Great review about reversible drug conjugation chemistry.
  Medline CASGoogle Scholar
• 30  Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev.64(9),866–884 (2012).▪ Interesting article introducing approaches to develop smart drug carriers.
  Medline CASGoogle Scholar
• 31  Radjenovic B, Radmilovic-Radjenovic M. Top down nano technologies in surface modification of materials. Cent. Eur. J. Phys.9(2),265–275 (2011).
  Google Scholar
• 32  Pattekari P, Zheng Z, Zhang X, Levchenko T, Torchilin V, Lvov Y. Top-down and bottom-up approaches in production of aqueous nanocolloids of low solubility drug paclitaxel. Phys. Chem. Chem. Phys.13(19),9014–9019 (2011).
  Medline CASGoogle Scholar
• 33  Shimomura M, Sawadaishi T. Bottom-up strategy of materials fabrication: a new trend in nanotechnology of soft materials. Curr. Opin. Coll. In.6(1),11–16 (2001).
  CASGoogle Scholar
• 34  Tu RS, Tirrell M. Bottom-up design of biomimetic assemblies. Adv. Drug Deliver. Rev.56(11),1537–1563 (2004).
  Medline CASGoogle Scholar
• 35  Lee SW, Chang WJ, Bashir R, Koo YM. ‘Bottom-up’ approach for implementing nano/microstructure using biological and chemical interactions. Biotechnol. Bioproc. E.12(3),185–199 (2007).
  CASGoogle Scholar
• 36  Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev.61(13),1220–1231 (2009).▪ Raises important questions in the drug delivery field.
  Medline CASGoogle Scholar
• 37  Kim S, Kim JH, Jeon O, Kwon IC, Park K. Engineered polymers for advanced drug delivery. Eur. J. Pharm. Biopharm.71(3),420–430 (2009).
  Medline CASGoogle Scholar
• 38  Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res.70(2),440–446 (2010).▪▪ Important article for understanding drug synergy.
  Medline CASGoogle Scholar
• 39  Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv.1(2),323–334 (2010).
  Medline CASGoogle Scholar
• 40  Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control Release126(3),187–204 (2008).
  Medline CASGoogle Scholar
• 41  Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J. Nanomater. doi:10.1155/2011/408675 (2011) (Epub ahead of print).
  Google Scholar
• 42  Kim DW, Kim SY, Kim HK et al. Multicenter Phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol.18(12),2009–2014 (2007).
  MedlineGoogle Scholar
• 43  Lee KS, Chung HC, Im SA et al. Multicenter Phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat.108(2),241–250 (2008).
  Medline CASGoogle Scholar
• 44  Nakajima TE, Yasunaga M, Kano Y et al. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int. J. Cancer122(9),2148–2153 (2008).
  Medline CASGoogle Scholar
• 45  Nagano T, Yasunaga M, Goto K et al. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. Clin. Cancer Res.15(13),4348–4355 (2009).
  Medline CASGoogle Scholar
• 46  Nagano T, Yasunaga M, Goto K et al. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. Int. J. Cancer127(11),2699–2706 (2010).
  Medline CASGoogle Scholar
• 47  Na HS, Lim YK, Jeong YI et al. Combination antitumor effects of micelle-loaded anticancer drugs in a CT-26 murine colorectal carcinoma model. Int. J. Pharm.383(1–2),192–200 (2010).
  Medline CASGoogle Scholar
• 48  Wang H, Zhao Y, Wu Y et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials32(32),8281–8290 (2011).
  Medline CASGoogle Scholar
• 49  Wang Z, Chui WK, Ho PC. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm. Res.28(3),585–596 (2011).
  MedlineGoogle Scholar
• 50  Shin HC, Alani AW, Cho H, Bae Y, Kolesar JM, Kwon GS. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol. Pharm.8(4),1257–1265 (2011).▪▪ Interesting article about drug carriers co-entrapping multiple drugs.
  Medline CASGoogle Scholar
• 51  Cho H, Kwon GS. Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging. ACS Nano5(11),8721–8729 (2011).
  Medline CASGoogle Scholar
• 52  Bae Y, Alani AW, Rockich NC, Lai TS, Kwon GS. Mixed pH-sensitive polymeric micelles for combination drug delivery. Pharm. Res.27(11),2421–2432 (2010).
  Medline CASGoogle Scholar
• 53  Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release122(3),324–330 (2007).
  Medline CASGoogle Scholar
• 54  Aryal S, Hu CM, Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharm.8(4),1401–1407 (2011).
  Medline CASGoogle Scholar
• 55  Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget3(3),236–260 (2012).
  MedlineGoogle Scholar
• 56  Kenmotsu H, Yasunaga M, Goto K et al. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer116(19),4597–4604 (2010).
  Medline CASGoogle Scholar
• 57  Sun TM, Du JZ, Yan LF, Mao HQ, Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials29(32),4348–4355 (2008).
  Medline CASGoogle Scholar
• 58  Huang HY, Kuo WT, Chou MJ, Huang YY. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J. Biomed. Mater. Res. A.97(3),330–338 (2011).
  MedlineGoogle Scholar
• 59  Benoit DS, Henry SM, Shubin AD, Hoffman AS, Stayton PS. pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol. Pharm.7(2),442–455 (2010).
  Medline CASGoogle Scholar
• 60  Zhu C, Jung S, Luo S et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials31(8),2408–2416 (2010).
  Medline CASGoogle Scholar
• 61  Sun TM, Du JZ, Yao YD et al. Simultaneous delivery of siRNA and paclitaxel via a ‘two-in-one’ micelleplex promotes synergistic tumor suppression. ACS Nano5(2),1483–1494 (2011).
  Medline CASGoogle Scholar
• 62  Guo PX. The emerging field of RNA nanotechnology. Nat. Nanotechnol.5(12),833–842 (2010).
  Medline CASGoogle Scholar
• 63  Shu D, Shu Y, Haque F, Abdelmawla S, Guo PX. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol.6(10),658–667 (2011).
  Medline CASGoogle Scholar
• 64  Afonin KA, Bindewald E, Yaghoubian AJ et al.In vitro assembly of cubic RNA-based scaffolds designed in silico. Nat. Nanotechnol.5(9),676–682 (2010).
  Medline CASGoogle Scholar
• 65  Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin. Drug Deliv.7(12),1329–1341 (2010).
  Medline CASGoogle Scholar
• 66  Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol.83(8),1104–1111 (2012).
  Medline CASGoogle Scholar
• 67  Yang T, Wang Y, Li Z et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine8(1),81–92 (2012).
  Medline CASGoogle Scholar
• 68  Wang Z, Ho PC. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials31(27),7115–7123 (2010).
  Medline CASGoogle Scholar
• 69  Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release136(1),21–29 (2009).
  Medline CASGoogle Scholar
• 70  van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res.67(10),4843–4850 (2007).
  Medline CASGoogle Scholar
• 71  van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J12(2),171–180 (2010).
  Medline CASGoogle Scholar
• 72  Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials31(2),358–365 (2010).
  Medline CASGoogle Scholar
• 73  Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano5(6),5202–5213 (2011).
  Medline CASGoogle Scholar
• 74  Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release161(2),175–187 (2011).
  MedlineGoogle Scholar
• 75  Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliver. Rev.61(10),768–784 (2009).▪ Useful review summarizing polymer micelle drug carriers.
  Medline CASGoogle Scholar
• 76  Lee HJ, Ponta A, Bae Y. Polymer nanoassemblies for cancer treatment and imaging. Ther. Deliv.1(6),803–817 (2010).
  Medline CASGoogle Scholar